Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer : National surgical adjuvant breast and bowel project protocol B-27BEAR, Harry D; ANDERSON, Stewart; PAIK, Soonmyung et al.Journal of clinical oncology. 2006, Vol 24, Num 13, pp 2019-2027, issn 0732-183X, 9 p.Article

Breast conservation in the treatment of breast cancer : Community-based experienceSWANSON, Gregory P; RYNEARSON, Kim; GEYER, Charles E et al.Southern medical journal (Birmingham). 2001, Vol 94, Num 3, pp 287-292, issn 0038-4348Article

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisCORTAZAR, Patricia; LIJUN ZHANG; SWAIN, Sandra M et al.Lancet (British edition). 2014, Vol 384, Num 9938, pp 164-172, issn 0140-6736, 9 p.Article

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20GONG TANG; SHAK, Steven; PAIK, Soonmynng et al.Breast cancer research and treatment. 2011, Vol 127, Num 1, pp 133-142, issn 0167-6806, 10 p.Article

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancerMARTIN, Miguel; BONNETERRE, Jacques; KONGMING WANG et al.European journal of cancer (1990). 2013, Vol 49, Num 18, pp 3763-3772, issn 0959-8049, 10 p.Article

Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27MAMOUNAS, Eleftherios P; ANDERSON, Stewart J; DIGNAM, James J et al.Journal of clinical oncology. 2012, Vol 30, Num 32, pp 3960-3966, issn 0732-183X, 7 p.Article

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessmentXIAOLEI ZHOU; CELLA, David; CAMERON, David et al.Breast cancer research and treatment. 2009, Vol 117, Num 3, pp 577-589, issn 0167-6806, 13 p.Article

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen : Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 TrialMAMOUNAS, Eleftherios P; JEONG, Jong-Hyeon; PAJON, Eduardo R et al.Journal of clinical oncology. 2008, Vol 26, Num 12, pp 1965-1971, issn 0732-183X, 7 p.Article

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analysesCAMERON, David; CASEY, Michelle; CHAN, Arlene et al.Breast cancer research and treatment. 2008, Vol 112, Num 3, pp 533-543, issn 0167-6806, 11 p.Article

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast CancerPAGANI, Olivia; REGAN, Meredith M; CIRUELOS, Eva et al.The New England journal of medicine. 2014, Vol 371, Num 2, pp 107-118, issn 0028-4793, 12 p.Article

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2―Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31PEREZ, Edith A; ROMOND, Edward H; SUMAN, Vera J et al.Journal of clinical oncology. 2011, Vol 29, Num 25, pp 3366-3373, issn 0732-183X, 8 p.Article

Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 TrialGANZ, Patricia A; LAND, Stephanie R; ERBAN, John K et al.Journal of clinical oncology. 2011, Vol 29, Num 9, pp 1110-1116, issn 0732-183X, 7 p.Article

HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast CancerPRESS, Michael F; FINN, Richard S; DANENBERG, Kathy et al.Clinical cancer research (Print). 2008, Vol 14, Num 23, pp 7861-7870, issn 1078-0432, 10 p.Article

Lapatinib plus capecitabine for HER2-positive advanced breast cancerGEYER, Charles E; FORSTER, John; SKARLOS, Dimosthenis et al.The New England journal of medicine. 2006, Vol 355, Num 26, pp 2733-2743, issn 0028-4793, 11 p.Article

Trastuzumab plus adjuvant chemotherapy for operable HER2-Positive breast cancerROMOND, Edward H; PEREZ, Edith A; SWAIN, Sandra M et al.The New England journal of medicine. 2005, Vol 353, Num 16, pp 1673-1684, issn 0028-4793, 12 p.Article

Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 TrialSWAIN, Sandra M; GONG TANG; BRUFSKY, Adam M et al.Journal of clinical oncology. 2013, Vol 31, Num 26, pp 3197-3204, issn 0732-183X, 8 p.Conference Paper

Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor―Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24CRAIG ALLRED, D; ANDERSON, Stewart J; LAND, Stephanie R et al.Journal of clinical oncology. 2012, Vol 30, Num 12, pp 1268-1273, issn 0732-183X, 6 p.Article

Preoperative Chemotherapy : Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27RASTOGI, Priya; ANDERSON, Stewart J; TAMKUS, Deimante et al.Journal of clinical oncology. 2008, Vol 26, Num 5, pp 778-785, issn 0732-183X, 8 p.Article

The Half Century of Clinical Trials of the National Surgical Adjuvant Breast and Bowel ProjectWICKERHAM, D. Lawrence; O'CONNELL, Michael J; WOLMARK, Norman et al.Seminars in oncology. 2008, Vol 35, Num 5, pp 522-529, issn 0093-7754, 8 p.Article

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trialsWAPNIR, Irene L; ANDERSON, Stewart J; MAMOUNAS, Eleftherios P et al.Journal of clinical oncology. 2006, Vol 24, Num 13, pp 2028-2037, issn 0732-183X, 10 p.Article

A Southwest Oncology Group randomized phase II study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancerLYMAN, Gary H; GREEN, Stephanie J; RAVDIN, Peter M et al.Breast cancer research and treatment. 2004, Vol 85, Num 2, pp 143-150, issn 0167-6806, 8 p.Article

A phase I and pharmocokinetic study of Exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignanciesGARRISON, Mitchell A; HAMMOND, Lisa A; DE JAGER, Robert L et al.Clinical cancer research. 2003, Vol 9, Num 7, pp 2527-2537, issn 1078-0432, 11 p.Article

Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31POGUE-GEILE, Katherine L; CHUNGYEUL KIM; TANIYAMA, Yusuke et al.Journal of the National Cancer Institute. 2013, Vol 105, Num 23, pp 1782-1788, issn 0027-8874, 7 p.Article

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast CancerBEAR, Harry D; GONG TANG; YOUNG, James A et al.The New England journal of medicine. 2012, Vol 366, Num 4, pp 310-320, issn 0028-4793, 11 p.Article

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2-Positive Breast CancerROMOND, Edward H; JEONG, Jong-Hyeon; FLYNN, Patrick J et al.Journal of clinical oncology. 2012, Vol 30, Num 31, pp 3792-3799, issn 0732-183X, 8 p.Article